Back to Search
Start Over
HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status
- Source :
- GlobeNewswire. January 10, 2024
- Publication Year :
- 2024
-
Abstract
- -- NDA accepted and granted Priority Review following its Breakthrough Therapy designation granted in January 2022 -- -- NDA is supported by data from successful Phase III ESLIM-01 trial in [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- GlobeNewswire
- Publication Type :
- News
- Accession number :
- edsgcl.779036452